Decision Diagnostics (DECN) Stock Price, News & Analysis

Company Overview

Decision Diagnostics Corp. operates as an in vitro diagnostics company focused on the development and commercialization of immunodiagnostic tests for autoimmune disorders. The company designs and manufactures proprietary enzyme-linked immunosorbent assay (ELISA) kits that detect biomarkers associated with rheumatoid arthritis, celiac disease and other immune-mediated conditions. Its intellectual property portfolio includes patents covering assay chemistries and analytical protocols aimed at improving diagnostic accuracy and efficiency.

The company’s core offerings include multi-analyte autoimmune panels and single-analyte test kits suitable for use in hospital, reference and specialty laboratories. Through partnerships with contract manufacturing organizations and distribution agreements with clinical service providers, Decision Diagnostics supplies products primarily in the United States. An in-house laboratory services division also provides custom assay development, validation and consultation services for biotechnology firms and academic research centers.

Founded in 1999, Decision Diagnostics has consistently pursued collaborations with research institutions to translate emerging biomarker discoveries into practical clinical applications. The company maintains a streamlined organizational structure and leverages external expertise for regulatory support and manufacturing scale-up. Management consists of industry professionals with extensive backgrounds in diagnostic development, commercialization and quality systems, guiding efforts to expand the company’s footprint in specialty and point-of-care testing markets.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 900 shs
• Average Volume: 203,429 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DECN Stock Analysis - Frequently Asked Questions

How do I buy shares of Decision Diagnostics?

Shares of DECN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Decision Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Decision Diagnostics investors own include Pfizer (PFE), Seagen (SGEN), Zimmer Biomet (ZBH), CenterPoint Energy (CNP), Chevron (CVX) and Devon Energy (DVN).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Computer Software
• Current Symbol: OTCMKTS:DECN
• CIK: N/A
• Web: www.decisiondiagnostics.co
• Phone: (805) 446-1973
• Fax: 805-446-1983
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.14